Nusano News

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET...

Nusano to Participate in Isotope and Radiopharmaceutical Conferences

Jul 20, 2023

Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.

Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development

May 15, 2023

Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.

Nusano Announces In-House Stable Isotope Program Led by Renowned Physicist Sarko Cherekdjian

May 11, 2023

Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.

Nusano to Participate in the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day

May 9, 2023

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.

Nusano to Host Key Opinion Leader Webinar on Isotope Production and Applications for Oncology Radio-pharmaceuticals

May 4, 2023

Nusano is hosting a virtual Key Opinion Leader (KOL) event on Friday, May 12, 2023 at 10 a.m. EST. The event will highlight the rapidly expanding and critically undersupplied medical radioisotopes market, including current limitations and what must be overcome to improve patient care and unlock market potential.

Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group

May 1, 2023

Nusano will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology (COST) Astatine-211 Working Group on May 4, 2023. Presentation materials will be available on the company’s website following the event.

Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event

Apr 20, 2023

Nusano’s Dr. Howard Lewin will take part in a virtual event hosted by Truist Securities on Friday, April 21, 2023, at 3:30 p.m. Eastern.

Nusano Announces Q1 2025 Opening Date for Medical Radioisotope Production Facility in Utah

Apr 17, 2023

Nusano’s breakthrough production facility will open Q1 2025 in West Valley City, Utah.

Nusano to Present at Jefferies Inaugural Radiopharma Innovation Summit

Mar 27, 2023

Nusano is a featured panelist and speaker at Jefferies Inaugural Radipharma Innovation Summit in New York City on April 3, 2023

Chris Lowe Named CEO

Jan 8, 2023

VALENCIA, Calif. and WEST VALLEY CITY, Utah, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced Chris Lowe as the company’s Chief Executive Officer. As Nusano progresses toward...